SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …

Background: To date, coronavirus disease 2019 (COVID-19) becomes increasingly fierce
due to the emergence of variants. Rapid herd immunity through vaccination is needed to …

Emerging severe acute respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) variants,
especially those of concern, may have an impact on the virus's transmissibility and …

Newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
are continuously posing high global public health concerns and panic resulting in waves of …

Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Our understanding of the still unfolding severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic would have been extremely limited without the study of the …

The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …

The rapid development of multiple vaccines providing strong protection from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement …

The novel coronavirus disease (COVID-19) pandemic remains a global public health crisis,
presenting a broad range of challenges. To help address some of the main problems, the …

Nirmatrelvir is a specific antiviral drug that targets the main protease (Mpro) of SARS-CoV-2
and has been approved to treat COVID-19,. As an RNA virus characterized by high mutation …